Brief: Castle Biosciences Q3 Basic EPS USD -0.26
02/11/2023 20:05
Nov 02 (Reuters) - Castle Biosciences Q3 net income USD -6.905 million. * Q3 revenue USD 61.493 million vs. IBES estimate USD 48.5 million * Q3 operating expenses USD 71.133 million * Q3 pretax profit USD -6.873 million * Q3 operating income USD -9.64 million * Q3 gross margin 78% * Q3 adjusted gross margin 81%
Recent news on Castle Biosciences
See all newsBrief: Castle Biosciences, - Opens New Laboratory And Office Facility In Scottsdale, Arizona
U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina
Castle Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Castle Biosciences beats Q2 revenue estimates, hikes forecast
Brief: Castle Biosciences Q2 Revenue USD 103.546 Million Vs. IBES Estimate USD 86.2 Million